Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
The production suspension impacts commercial and clinical trial supply
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
Subscribe To Our Newsletter & Stay Updated
